We are live on ! Find out more
OC

Oppenheimer & Co Portfolio holdings

AUM $8.21B
1-Year Est. Return 28.81%
This Fund
S&P 500
This Quarter Est. Return
+9.03%
1 Year Est. Return
+28.81%
3 Year Est. Return
+92.54%
5 Year Est. Return
+114.67%
10 Year Est. Return
+429.8%
AUM
$5.72B
AUM Growth
+$377M
Cap. Flow
-$47.5M
Cap. Flow %
-0.83%
Top 10 Hldgs %
18.31%
Holding
1,615
New
130
Increased
604
Reduced
665
Closed
130

Sector Composition

Rank Sector Weight
1 Technology 19.17%
2 Financials 10.88%
3 Healthcare 10.31%
4 Consumer Discretionary 9.37%
5 Industrials 8.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
RIGL icon
1426
Rigel Pharmaceuticals
RIGL
$704M
$151K ﹤0.01%
5,680
-459
-7% -$13.8K
JRO
1427
DELISTED
Nuveen Floating Rate Income Opportunty Fund
JRO
$149K ﹤0.01%
14,735
+465
+3% +$4.66K
VISN
1428
Vistance Networks Inc
VISN
$2.64B
$147K ﹤0.01%
13,350
-24,000
-64% -$263K
CS
1429
DELISTED
Credit Suisse Group
CS
$146K ﹤0.01%
15,133
-564
-4% -$5.64K
FMAC
1430
DELISTED
FirstMark Horizon Acquisition Corp.
FMAC
$142K ﹤0.01%
+14,337
New +$142K
IDE
1431
Voya Infrastructure, Industrials and Materials Fund
IDE
$196M
$139K ﹤0.01%
+11,500
New +$139K
JRS icon
1432
Nuveen Real Estate Income Fund
JRS
$250M
$133K ﹤0.01%
+10,362
New +$121K
SLNO
1433
DELISTED
Soleno Therapeutics
SLNO
$123K ﹤0.01%
20,058
-22,551
-53% -$237K
INO icon
1434
Inovio Pharmaceuticals
INO
$54M
$121K ﹤0.01%
+2,020
New +$162K
MGF
1435
Aberdeen Government Markets Income Fund
MGF
$91.6M
$120K ﹤0.01%
28,283
+152
+0.5% +$648
ATXS
1436
DELISTED
Astria Therapeutics
ATXS
$118K ﹤0.01%
21,816
+9,567
+78% +$62.9K
NSL
1437
DELISTED
NUVEEN SENIOR INCM FD
NSL
$118K ﹤0.01%
20,000
CGC
1438
Canopy Growth
CGC
$388M
$116K ﹤0.01%
1,322
-283
-18% -$33.6K
PDSB icon
1439
PDS Biotechnology
PDSB
$39.1M
$114K ﹤0.01%
14,000
+1,350
+11% +$14.5K
VERU icon
1440
Veru
VERU
$35.6M
$113K ﹤0.01%
1,919
-1,135
-37% -$86.8K
TUFN
1441
DELISTED
Tufin Software Technologies Ltd.
TUFN
$112K ﹤0.01%
10,600
-4,000
-27% -$38.3K
PSEC icon
1442
Prospect Capital
PSEC
$1.08B
$111K ﹤0.01%
13,222
VLDR
1443
DELISTED
Velodyne Lidar, Inc. Common Stock
VLDR
$109K ﹤0.01%
23,442
-177,370
-88% -$1.04M
ADIL
1444
Adial Pharmaceuticals
ADIL
$7.2M
$104K ﹤0.01%
62
MFM
1445
Aberdeen Municipal Income Fund
MFM
$222M
$101K ﹤0.01%
14,497
MLSS icon
1446
Milestone Scientific
MLSS
$34.6M
$98K ﹤0.01%
47,500
+10,000
+27% +$22K
COMP icon
1447
Compass
COMP
$8.56B
$95K ﹤0.01%
10,400
-23,028
-69% -$252K
NAGE
1448
Niagen Bioscience
NAGE
$264M
$94K ﹤0.01%
25,110
+2,900
+13% +$15.7K
CLNN icon
1449
Clene
CLNN
$64.4M
$91K ﹤0.01%
+1,111
New +$119K
MNKD icon
1450
MannKind Corp
MNKD
$1.27B
$91K ﹤0.01%
20,800
-3,000
-13% -$13.9K

Similar funds

Oppenheimer & Co's Q4 2021 Portfolio in Review

As of Q4 2021, Oppenheimer & Co held 1,615 positions worth $5.72B, up 7.1% from $5.34B the previous quarter. Its ten largest holdings account for 18% of the portfolio.

Oppenheimer & Co's Q4 2021 filing shows 130 new, 604 increased, 665 reduced and 130 closed positions. Its largest new stake was Invesco Total Return Bond ETF: 132,838 shares worth $7.49M. The largest sale was Global X S&P 500 Covered Call ETF, an estimated $49.9M.

By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 18% a quarter earlier, followed by Financials and Healthcare.

  • Oppenheimer & Co's largest Q4 2021 buy was Invesco Total Return Bond ETF: 132,838 shares worth $7.49M.
  • Oppenheimer & Co added most to Canadian Pacific Kansas City in Q4 2021, an estimated $7.48M increase.
  • Oppenheimer & Co's biggest Q4 2021 reduction was Global X S&P 500 Covered Call ETF, cutting an estimated $49.9M.
  • Oppenheimer & Co fully exited Kansas City Southern in Q4 2021, selling an estimated $6.61M.
  • Oppenheimer & Co's ten largest holdings make up 18% of its $5.72B portfolio in Q4 2021.
  • Oppenheimer & Co opened 130 new positions and closed 130 in Q4 2021.
  • Oppenheimer & Co's portfolio value rose 7.1% quarter-over-quarter to $5.72B.

Based on Oppenheimer & Co's 13F filing for Q4 2021, filed 2 Feb 2022.